PVI
ARCT icon

Pura Vida Investments’s Arcturus Therapeutics ARCT Stock Holding History

Pura Vida Investments’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$848K – 84
2022
Q4 		$848K Buy
+50,000
New +$872K 0.04% 147

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Pura Vida Investments's ARCT Position: Q1 2023 in Review

Pura Vida Investments sold out of Arcturus Therapeutics (ARCT) in Q1 2023, closing a stake of 50,000 shares — an estimated $848K sold.

Pura Vida Investments first reported a position in ARCT in Q4 2022 and held it in 1 quarter. The position peaked at $848K in Q4 2022. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2023.

  • Pura Vida Investments reported no remaining Arcturus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 50,000 Arcturus Therapeutics shares in Q1 2023, an estimated $848K.
  • Pura Vida Investments first reported a position in Arcturus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Pura Vida Investments's Arcturus Therapeutics position peaked at $848K in Q4 2022.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.